Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 13/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073788 | 0.88 | PIK3CA (0.42) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073611 | 0.84 | CDK4 (0.41) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073777 | 0.83 | BRAF (0.43) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073998 | 0.83 | PIK3CA (0.47) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073648 | 0.81 | FGFR1 (0.44) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073488 | 0.80 | CDK4 (0.50) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6074378 | 0.79 | SYK (0.56) | MAPK8MAPK9MAPK14 | |
| SCHEMBL4353721 | 0.79 | PIK3CA (0.73) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL6073553 | 0.78 | EPHX1 (0.56) | — | |
| SCHEMBL6073764 | 0.76 | PIK3CA (0.53) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | claimed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | claimed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | PIK3CA 299/4885MAPK8 240/4885MAPK9 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.